Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2021; 79(09): 789-794
DOI: 10.1590/0004-282X-ANP-2020-0425
Article

Investigation of serum vaspin, visfatin, chemerin and IL-18 levels in migraine patients

Investigação dos níveis séricos de vaspina, visfatina, quemerina e IL-18 em pacientes com migrânea
Ahmet Dönder 
1   Mardin Artuklu University, Vocational School of Health Services, Department of Medical Laboratory, Mardin, Turkey.
,
Vugar Cafer 
2   Istinye University, Department of Neurology, Istanbul, Turkey.
,
Ahmet Yilmaz 
3   Dicle University, Faculty of Medicine, Department of Family Medicine, Diyarbakır, Turkey.
,
Hamza Aslanhan 
3   Dicle University, Faculty of Medicine, Department of Family Medicine, Diyarbakır, Turkey.
,
Adalet Arikanoğlu 
4   Dicle University, Faculty of Medicine, Department of Neurology, Diyarbakır, Turkey
› Author AffiliationsThis study was supported by the Directorate of Scientific Research Projects of Dicle University (project number: Atatürk-SHMYO.17.001)
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background: Migraines are headaches caused by changes in the trigeminovascular metabolic pathway. Migraine headache attacks are associated with neurovascular inflammation, but their pathophysiological mechanisms have not been fully explained. Objective: To investigate the relationship between serum vaspin, visfatin, chemerin and interleukin-18 (IL-18) levels and the frequency of attacks in migraine headache. Methods: Three groups were established: migraine with aura (n = 50), migraine without aura (n = 50) and control group (n = 50). The migraine diagnosis was made in accordance with the International Classification of Headache Disorders-III beta diagnostic criteria. The analyses on serum vaspin, visfatin, chemerin and IL-18 levels were performed using the enzyme-linked immunosorbent assay method. Results: The serum vaspin, visfatin, chemerin and IL-18 levels were found to be significantly higher in the migraine patients than in the control group (p < 0.01). No statistically significant differences in serum vaspin, visfatin, chemerin and IL-18 levels were found among the migraine patients during attacks or in the interictal period (p>0.05). The serum visfatin and chemerin levels of the migraine patients were positively correlated with their serum IL-18 levels (p < 0.01), while their serum chemerin and visfatin levels were positively correlated with their serum vaspin levels (p < 0.05). Conclusions: This study showed that these biomarkers may be related to migraine pathogenesis. Nonetheless, we believe that more comprehensive studies are needed in order to further understand the role of vaspin, visfatin, chemerin and IL-18 levels in the pathophysiology of migraine headaches.

Resumo

Introdução: A migrânea é causada por alterações nas vias metabólicas do sistema trigeminovascular. Crises de migrânea estão associadas à inflamação neurovascular, mas seus mecanismos patofisiológicos ainda não são totalmente explicados. Objetivo: Investigar a relação entre níveis séricos de vaspina, visfatina, quemerina e interleucina-18 (IL-18) e a frequência de crises de migrânea. Métodos: Três grupos foram formados: migrânea com aura (n = 50), migrânea sem aura (n = 50) e grupo controle (n = 50). A migrânea foi diagnosticada de acordo com os critérios da Classificação Internacional das Cefaleias (ICHD-III). As análises dos níveis séricos de vaspina, visfatina, quemerina e IL-18 foram realizadas utilizando-se o método imunoenzimático (ELISA). Resultados: Os níveis séricos de vaspina, visfatina, quemerina e interleucina-18 (IL-18) foram significativamente mais elevados em pacientes com migrânea do que no grupo controle (p < 0.01). Nenhuma diferença estatisticamente significativa foi observada nos níveis séricos de vaspina, visfatina, quemerina e interleucina-18 (IL-18) entre os pacientes com migrânea durante crises ou no período interictal (p>0,05). Os níveis séricos de visfatina e quemerina em pacientes com migrânea se correlacionaram positivamente com os níveis séricos de IL-18 (p < 0,01), ao passo que os níveis séricos de quemerina e visfatina se correlacionaram positivamente com os níveis séricos de vaspina (p < 0,05). Conclusões: Este estudo demonstrou que estes biomarcadores podem estar relacionados à patogênese da migrânea. Contudo, acreditamos que estudos mais abrangentes são necessários a fim de melhor compreendermos o papel dos níveis de vaspina, visfatina, quemerina e IL-18 na fisiopatologia da migrânea.

Keywords:

Chimerin 1 - Interleukin-18 - Inflammation - Migraine without Aura - Pathogenesis Homeopathic - Vaspin - Nicotinamide Phosphoribosyltransferase

Palavras-chave:

Quimerina 1 - Interleucina-18 - Inflamação - Enxaqueca sem Aura - Patogênese Homeopática - Vaspina - Nicotinamida Fosforribosiltransferase

Authors’ contributions:

The authors contributed equally to data collection, methodology, literature review, material collection, statistical analysis, data evaluation, article writing and editing.


Support:

This study was supported by the Directorate of Scientific Research Projects of Dicle University (project number: Atatürk-SHMYO.17.001)




Publication History

Received: 09 September 2020

Accepted: 29 November 2020

Article published online:
01 June 2023

© 2021. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Hamed SA. The vascular risk associations with migraine: relation to migraine susceptibility and progression. Atherosclerosis. 2009 Jul 1;205(1):15-22. https://doi.org/10.1016/j.atherosclerosis.2008.10.016
  • 2 Sachdev A, Marmura MJ. Metabolic syndrome and migraine. Front Neurol. 2012 Nov 19;3:161. https://doi.org/10.3389/fneur.2012.00161
  • 3 Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun. 2006 Jan 6;339(1):430-6. https://doi.org/10.1016/j.bbrc.2005.11.039
  • 4 Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs. 2008 Mar 6;17(3):327-33. https://doi.org/10.1517/13543784.17.3.327
  • 5 Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008 Nov;14(11-12):741-51. https://doi.org/10.2119/2008-00058.Rabe
  • 6 Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: visfatin novel mediator of innate immunity. J Leukoc Biol. 2008 Apr;83(4):804-16. https://doi.org/10.1189/jlb.0807581
  • 7 Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007 Feb 1;178(3):1748-58. https://doi.org/10.4049/jimmunol.178.3.1748
  • 8 Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J, Handel TM, et al. Chemerin activation by serine proteases of the coagulation fibrinolytic, and inflammatory cascades. J Biol Chem. 2005 Oct 14;280(41):34661-6. https://doi.org/10.1074/jbc.M504868200
  • 9 Gorlaski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007 Sep 21;282(38):28175-88. https://doi.org/10.1074/jbc.M700793200
  • 10 Takahasi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, Kitazawa R, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett. 2008 Mar 5;582(5):573-8. https://doi.org/10.1016/j.febslet.2008.01.023
  • 11 Leslie JA, Meldrum KK. The role of interleukin-18 in renal injury. J Surg Res. 2008 Mar 1;145(1):170-5. https://doi.org/10.1016/j.jss.2007.03.037
  • 12 Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013 Jul;33(9):629-808. https://doi.org/10.1177/0333102413485658
  • 13 Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ. Brainstem activation specific to migraine headache. Lancet. 2001 Mar 31;357(9261):1016-7. https://doi.org/10.1016/S0140-6736(00)04250-1
  • 14 Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002 Jan 24;346(4):257-70. https://doi.org/10.1056/NEJMra010917
  • 15 Zhang X, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R. Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol. 2011 May;69(5):855-65. https://doi.org/10.1002/ana.22329
  • 16 Matsui H, Tsutsumi A, Sugihara M, Suzuki T, Iwanami K, Kohno M, et al. Visfatin (pre-B cell colony-enhancing factor) gene expression in patients with rheumatoid arthritis. Ann Rheum Dis. 2008 Apr;67(4):571-2. https://doi.org/10.1136/ard.2007.077578
  • 17 Adya R, Tan BK, Chen J, Randeva HS. Nuclear factor-kappa B induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care. 2008 Apr;31(4):758-60. https://doi.org/10.2337/dc07-1544
  • 18 Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: visfatin novel mediator of innate immunity. J Leukoc Biol. 2008 Apr;83(4):804-16. https://doi.org/10.1189/jlb.0807581
  • 19 Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007 Feb 1;178(3):1748-58. https://doi.org/10.4049/jimmunol.178.3.1748
  • 20 Kadoglou NP, Fotiadis G, Lambadiari V, Maratou E, Dimitriadis G, Liapis CD. Serum level of novel adipokines in patients with ischemic stroke: potential contribution to diagnosis and prognosis. Peptides. 2014 Jul;57:12-6. https://doi.org/10.1016/j.peptides.2014.04.008
  • 21 Yin C-G, Jiang L, Tang B, Zhang H, Qian Q, Niu G-Z. Prognostic significance of plasma visfatin level in acute ischemic stroke. Peptides. 2013 Apr;42:101-4. https://doi.org/10.1016/j.peptides.2013.01.005
  • 22 Li C, Zhu Q, He Q, Wang J, Wang F, Zhang H. Plasma levels of Cyclooxygenase-2 (COX-2) and visfatin during different stages and different subtypes of migraine headaches. Med Sci Monit. 2017 Jan 3;23:24-8. https://doi.org/10.12659/MSM.899269
  • 23 Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007 Sep 21;282(38):28175-88. https://doi.org/10.1074/jbc.M700793200
  • 24 Roh S-G, Song S-H, Choi K-C, Katoh K, Wittamer V, Parmentier M, et al. Chemerin-a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun. 2007 Nov 3;362(4):1013-8. https://doi.org/10.1016/j.bbrc.2007.08.104
  • 25 Zylla S, Pietzner M, Kühn J-P, Völzke H, Dörr M, Nauck M, et al. Serum chemerin is associated with inflammatory and metabolic parameters-results of a population-based study. Obesity (Silver Spring). 2017 Feb;25(2):468-75. https://doi.org/10.1002/oby.21735
  • 26 Sell H, Divoux A, Poitou C, Basdevant A, Bouillot J-L, Bedossa P, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2010 Jun 1;95(6):2892-6. https://doi.org/10.1210/jc.2009-2374
  • 27 Wittamer V, Franssen J-D, Vulcano M, Mirjolet J-F, Le Poul E, Migeotte I, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003 Oct 6;198(7):977-85. https://doi.org/10.1084/jem.20030382
  • 28 Berg H, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002 Mar 1;13(2):84-9. https://doi.org/10.1016/s1043-2760(01)00524-0
  • 29 Leal V de O, Mafra D. Adipokines in obesity. Clin Chim Acta. 2013 Apr 18;419:87-94. https://doi.org/10.1016/j.cca.2013.02.003
  • 30 Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10610-5. https://doi.org/10.1073/pnas.0504703102
  • 31 Binshtok AM, Wang H, Zimmermann K, Amaya F, Vardeh D, Shi L, et al. Nociceptors are interleukin-1beta sensors. J Neurosci. 2008 Dec 24;28(52):14062-73. https://doi.org/10.1523/JNEUROSCI.3795-08.2008
  • 32 Schaible H-G, von Banchet GS, Boettger MK, Brauer R, Gajda M, Richter F, et al. The role of proinflammatory cytokines in the generation and maintenance of joint pain. Ann N Y Acad Sci. 2010 Apr 13;1193(1):60-9. https://doi.org/10.1111/j.1749-6632.2009.05301.x
  • 33 Dinarello CA. IL-18: a TH1-inducing: proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol. 1999 Jan 1;103(1):11-24. https://doi.org/10.1016/S0091-6749(99)70518-X
  • 34 Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001 Mar;12(1):53-72. https://doi.org/10.1016/S1359-6101(00)00015-0
  • 35 Cucci A, Barbero P, Clerico M, Ferrero B, Versino E, Contessa G, et al. Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose. J Neuroimmunol. 2010 Sep 14;226(1-2):150-7. https://doi.org/10.1016/j.jneuroim.2010.05.038
  • 36 Silva FA, Rueda-Clausen CF, Silva SY, Zarruk JG, Guzmán JC, Morillo CA, et al. Endothelial function in patients with migraine during the interictal period. Headache. 2007 Jan;47(1):45-51. https://doi.org/10.1111/j.1526-4610.2006.00532.x
  • 37 Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005 Jan 21;307(5708):426-30. https://doi.org/10.1126/science.1097243
  • 38 Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007 Oct 1;148(10):4687-94. https://doi.org/10.1210/en.2007-0175